Breaking News Instant updates and real-time market news.

AXON

Axovant Sciences

$23.05

0.16 (0.70%)

, SFTBY

SoftBank

$40.36

-0.795 (-1.93%)

08:53
08/09/17
08/09
08:53
08/09/17
08:53

SoftBank Vision Fund invests $1.1B in Ramaswamy's Roivant

Roivant Sciences announced a $1.1B equity investment led by the SoftBank (SFTBY) Vision Fund. The investment, which includes existing shareholder participation, is intended to "accelerate the launch of new subsidiaries within and beyond the biopharmaceutical industry." Vivek Ramaswamy, Founder and CEO of Roivan, said, "We are pleased to welcome the SoftBank Vision Fund as a new investor in Roivant, and we are grateful for the continued support of our existing shareholders. I admire SoftBank's long-term vision and I believe they will add significant strategic value to Roivant in the next phase of our growth." Axovant Sciences (AXON) is a subsidiary of Roivant.

AXON

Axovant Sciences

$23.05

0.16 (0.70%)

SFTBY

SoftBank

$40.36

-0.795 (-1.93%)

AXON Axovant Sciences
$23.05

0.16 (0.70%)

07/12/17
OPCO
07/12/17
NO CHANGE
OPCO
Outperform
Axovant Sciences upcoming results may drive valuation upside, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Axovant Sciences faces two substantial binary events including the Phase 3 MINDSET study results at the end of September and the Phase 2 HEADWAY study results in Q4. The combination of these two events could drive up to 100% valuation upside, he contends. Further, the analyst believes the company is positioned to deliver the first new symptomatic Alzheimer's Disease drug approved by the FDA in over a decade. Olson reiterates an Outperform rating on the shares.
07/10/17
JEFF
07/10/17
INITIATION
Target $40
JEFF
Buy
Axovant Sciences initiated with a Buy at Jefferies
Jefferies analyst Michael Yee initiated Axovant Sciences with a Buy and a $40 price target.
06/14/17
OPCO
06/14/17
NO CHANGE
Target $30
OPCO
Outperform
Axovant Sciences price target raised to $30 from $26 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Axovant Sciences to $30 after leaving a meeting with management "incrementally more positive." The analyst is "encouraged" by management's vision which he says extends beyond dementia into other areas of high unmet need within neurology. He believes the focus on dementia with Lewy bodies and Lewy body dementia, which includes Parkinson's disease dementia, could "create significant value for shareholders." Olson sees a favorable risk/reward profile for intepirdine in the Phase 3 Mindset study with top-line results due in late September. He keeps an Outperform rating on Axovant.
04/17/17
JEFF
04/17/17
NO CHANGE
Target $31
JEFF
Buy
Jefferies sees Axovant shares hitting $5 or $90 on Sept. data
Jefferies analyst Biren Amin last week hosted investor meetings with Axovant Sciences' incoming CEO David Hung and Vivek Ramaswamy, who is transitioning to CEO of privately held Roivant. He notes the stock is up 45% since the announcement. "This is the stupidest thing I've ever heard," Hung said of the investor theory that he believes intepirdine will fail, Amin tells investors in a research note. It seems Axovant's profile fit what Hung was looking for and he conducted extensive due diligence on both intepirdine and nelotanserin, the analyst writes. He adds that the new CEO believes both products, in aggregate, offer five opportunities for value creation. Regarding the late September Phase III readout for intepirdine in mild to moderate Alzheimer's disease, Amin believes Axovant shares could trade to $80-$90 with strong improvement on the Alzheimer's disease assessment scale, or ADS-cog, of 1.5 point at 24 weeks and positive ADCS-adl, or Alzheimer's disease cooperative study - activities of daily living outcome. With a more moderate outcome where ADS-cog ranges between 0.7 and 1.3 point improvement and ADCS-adl does not achieve statistical significance, the analyst thinks the shares could still range higher to $45-$50. If the Mindset trial fails, he thinks the shares could drop to $5. Axovant closed Thursday up $2.20 to $22.
SFTBY SoftBank
$40.36

-0.795 (-1.93%)

07/31/17
JPMS
07/31/17
NO CHANGE
Target $450
JPMS
Overweight
Charter offer would likely have to be at least $500 per share, says JPMorgan
JPMorgan analyst Philip Cusick believes SoftBank (SFTBY) is one of the few companies that could offer a big enough price to take control of Charter Communications (CHTR). While a deal is not very likely, Softbank Chairman Masayoshi Son "is never to be counted out as a buyer," Cusick tells investors in a research note. He believes a Charter acquisition offer would likely have to be in the $500 per share or higher range. Charter shares in premarket trading are up $31.74 to $402 after the Wall Street Journal reported Friday night that SoftBank has interest in merging the company with Sprint. Cusick estimates annual synergies between Sprint (S) and Charter could be around $2B, with minimal cost to integrate versus a Sprint and T-Mobile (TMUS) merger "which would have more eventual cost savings but cost much more to integrate." A Sprint and Charter deal would not have a difficult regulatory review, the analyst believes. Cusick adds that if Charter looked like it was going to sell to Softbank, Comcast (CMCSA) would have to decide if it ever did want to buy Charter and "move more quickly with an even bigger premium."
01/23/17
JPMS
01/23/17
NO CHANGE
JPMS
JPMorgan says odds of T-Mobile, Sprint merger have 'increased dramatically'
JPMorgan analyst Philip Cusick believes T-Mobile (TMUS), Sprint (S) and DISH (DISH) are in play and that a combination of any of them could happen. In addition, each of the three companies could become targets for larger wireless players, domestic cable companies, Internet giants and foreign buyers, Cusick tells investors in a research note. He thinks the likelihood for a Sprint and T-Mobile tie-up in the near term has "increased dramatically" since September, from 10% to over 35%, including now a greater than 50% chance of announcement and 70% chance of approval if announced. Parents Softbank (SFTBY) and Deutsche Telekom (DTEGY) have increased their preference for a deal in the last six months and that the value of $5B of annual synergies "is enough to smooth over most disagreements on relative value," Cusick contends. He sees the most likely case as Sprint/Softbank buying T-Mobile, but feels a more even merger or even Deutsche Telekom/T-Mobile paying a premium to retain a majority of the combined company is possible.
09/12/16
DBAB
09/12/16
DOWNGRADE
DBAB
Hold
SoftBank downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Peter Milliken downgraded Softbank (SFTBY) to Hold saying the company's rebuilding efforts should take time. The analyst expects the stock to trade largely in line with Alibaba (BABA), Sprint (S) and the yen over the next 12 months, and he feels much of the upside has already been realized in the first two.

TODAY'S FREE FLY STORIES

KSU

Kansas City Southern

$105.80

-0.07 (-0.07%)

17:45
08/18/17
08/18
17:45
08/18/17
17:45
Hot Stocks
Kansas City Southern director Henry Maier buys 3,000 shares »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RXII

RXi Pharmaceuticals

$0.58

-0.02 (-3.36%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on RXi Pharmaceuticals »

RXi Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WIN

Windstream

$1.98

0.06 (3.13%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Hot Stocks
Windstream CEO acquires 25,381 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$2.44

-0.22 (-8.27%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.20

-0.03 (-0.11%)

17:25
08/18/17
08/18
17:25
08/18/17
17:25
Hot Stocks
ValueAct raises stake inTrinity Industries to 11% from 9.8% »

As of this date, ValueAct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTN

Lpath

17:11
08/18/17
08/18
17:11
08/18/17
17:11
Hot Stocks
Breaking Hot Stocks news story on Lpath »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$48.63

0.12 (0.25%)

17:08
08/18/17
08/18
17:08
08/18/17
17:08
Hot Stocks
Progressive CFO sells 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$172.57

-0.32 (-0.19%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Thermo Fisher director sells 11,318 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SMBC

Southern Missouri Bancorp

$31.18

-0.05 (-0.16%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Southern Missouri Bancorp and Southern Missouri Bancshares to merge »

Southern Missouri Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:58
08/18/17
08/18
16:58
08/18/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ended advisory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says never had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:56
08/18/17
08/18
16:56
08/18/17
16:56
Hot Stocks
Icahn no longer special advisor to President Trump on regulatory reform issues »

Carl Icahn, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:55
08/18/17
08/18
16:55
08/18/17
16:55
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:49
08/18/17
08/18
16:49
08/18/17
16:49
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$30.38

0.76 (2.57%)

16:48
08/18/17
08/18
16:48
08/18/17
16:48
Hot Stocks
Micron director sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

INSY

Insys Therapeutics

$9.17

-0.11 (-1.19%)

16:42
08/18/17
08/18
16:42
08/18/17
16:42
Hot Stocks
Insys agrees to pay $4.45M to settle opioid marketing suit »

Illinois Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

16:34
08/18/17
08/18
16:34
08/18/17
16:34
Syndicate
Breaking Syndicate news story on Akari Therapeutics »

Akari Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.11

-0.04 (-0.44%)

16:32
08/18/17
08/18
16:32
08/18/17
16:32
Hot Stocks
Jamba receives expected letter from Nasdaq »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIL

Hill International

$4.50

0.2 (4.65%)

16:31
08/18/17
08/18
16:31
08/18/17
16:31
Hot Stocks
Hill International receives NYSE notice regarding late Form 10-Q filing »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$55.65

-0.47 (-0.84%)

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Periodicals
Target ends relationship with food startup Hampton Creek, Bloomberg says »

After an internal review,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Options
Preliminary option volume of 23.2M today »

Preliminary option volume…

NBEV

New Age Beverages

$3.51

-0.49 (-12.25%)

16:29
08/18/17
08/18
16:29
08/18/17
16:29
Hot Stocks
New Age Beverages director sells nearly 42,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

, ESV

Ensco

$4.28

0.12 (2.88%)

16:24
08/18/17
08/18
16:24
08/18/17
16:24
Hot Stocks
Atwood Oceanics, Ensco file proxy materials in connection with pending merger »

Ensco (ESV) and Atwood…

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

ESV

Ensco

$4.28

0.12 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$83.76

-0.1 (-0.12%)

16:23
08/18/17
08/18
16:23
08/18/17
16:23
Periodicals
Nestle faces potential fraud suit over Poland Spring marketing, WSJ says »

Nestle is facing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.